<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03743038</url>
  </required_header>
  <id_info>
    <org_study_id>FX2018-23</org_study_id>
    <nct_id>NCT03743038</nct_id>
  </id_info>
  <brief_title>A Study Comparing Two Topicals in the Treatment of Acne Vulgaris</brief_title>
  <official_title>A Randomized, Evaluator-Blinded, Bilateral Comparison Study of Two Topicals in the Treatment of Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Foamix Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Foamix Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Randomized, Evaluator-Blinded, Bilateral Comparison Study to Evaluate the Safety and
      Efficacy of Two Topicals in the Treatment of Subjects With Acne Vulgaris (Study FX2018-23).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Evaluator-Blinded, Bilateral Comparison Study to Evaluate the Safety and
      Efficacy of Two Topicals in the Treatment of Subjects With Acne Vulgaris. Eligible subjects
      will be randomized (1:1) to treatent with Test Article A to one side of the face versus Test
      Article B on the contralateral side.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 19, 2018</start_date>
  <completion_date type="Actual">February 11, 2019</completion_date>
  <primary_completion_date type="Actual">February 11, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eligible subjects will be randomized (1:1) to treatment with Test Article A to one side of the face versus Test Article B on the contralateral side.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>IGA Assessment</measure>
    <time_frame>6 weeks</time_frame>
    <description>Severity of acne vulgaris assessed by investigator Global Assessment (IGA) Treatment A&gt; Treatment B, Treatment A= Treatment B, Treatment A&lt; Treatment B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory Lesion Count</measure>
    <time_frame>6 weeks</time_frame>
    <description>The absolute change from baseline in the inflammatory lesion count at week 6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-inflammatory Lesion Count</measure>
    <time_frame>6 weeks</time_frame>
    <description>The absolute change from baseline in the non inflammatory lesion count at week 6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sebum assessment</measure>
    <time_frame>2, 4, 6 and 7 weeks</time_frame>
    <description>Sebum assessment relative to Baseline versus Weeks 2, 4, 6, and 7, within subject Treatment A versus Treatment B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Inflammatory Lesion Count</measure>
    <time_frame>6 weeks</time_frame>
    <description>The percent change from baseline in the inflammatory lesion count at week 6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Non-inflammatory Lesion Count</measure>
    <time_frame>6 weeks</time_frame>
    <description>The percent change from baseline in the non inflammatory lesion count at week 6</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Trans Epidermal Water Loss (TEWL) assessment</measure>
    <time_frame>2, 4, 6 and 7 weeks</time_frame>
    <description>TEWL assessment relative to Baseline versus Weeks 2, 4, 6, and 7,</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>FMX101 vehicle</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FMX101 hydrophobic oil based vehicle (Test Article A) topically applied daily for six weeks on one side of the face (in a split-face model)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydro-alcohol solution base</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Hydro-alcohol solution based vehicle (Test Article B) topically applied daily for six weeks on the contralateral side of the face (in a split-face model)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FMX101 vehicle</intervention_name>
    <description>FMX101 vehicle - hydrophobic oil based vehicle (Test Article A)</description>
    <arm_group_label>FMX101 vehicle</arm_group_label>
    <other_name>Test Article A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Hydro-alcohol solution</intervention_name>
    <description>Hydro-alcohol solution based vehicle (Test Article B)</description>
    <arm_group_label>Hydro-alcohol solution base</arm_group_label>
    <other_name>Test Article B</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Has facial acne vulgaris with:

             16 inflammatory lesions (papules, pustules) The inflammatory lesion count on the right
             and left side of the face should be similar IGA score of moderate (3) on both the
             right and left side of the face

        Exclusion Criteria:

          -  Acne conglobata, acne fulminans, secondary acne (chloracne, drug-induced acne), or any
             dermatological condition of the face or facial hair (eg, beard, sideburns, mustache)
             that could interfere with the clinical evaluations.

          -  More than two facial nodules/cysts

          -  Sunburn on the face
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Site #01</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 10, 2018</study_first_submitted>
  <study_first_submitted_qc>November 14, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 15, 2018</study_first_posted>
  <last_update_submitted>April 2, 2019</last_update_submitted>
  <last_update_submitted_qc>April 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Minocycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

